Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 61Recurrence 10Lymphoma 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia 1Kidney Failure, Chronic 1

Interventions

Octreotide 5Everolimus 4pasireotide 3lanreotide 3ganitumab 2gallium Ga 68 dotatate 2cabozantinib 2Nivolumab 2Erlotinib Hydrochloride 2surufatinib 1pertuzumab 1nintedanib 1ibrutinib 1fosbretabulin 1conatumumab 1cixutumumab 1carfilzomib 1arginyllysine 1aflibercept 1Temozolomide 1Sunitinib 1Somatostatin 1Random Allocation 1Ramucirumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Capecitabine 1Bevacizumab 1Axitinib 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × carfilzomib × Clear all
NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
62 enrolled 10 charts
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡